# Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study

Source: https://onco.cc/trials/nct03381274/  
OnCo record `nct03381274` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Oleclumab and Osimertinib in non-small-cell lung cancer, run by MedImmune LLC, active and no longer recruiting.

## Summary

Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study is a phase 1/2 interventional study registered as NCT03381274 by MedImmune LLC, with 43 participants enrolled, started 2018-05-08 and due to reach its primary completion in 2021-05-24. Interventions recorded: Oleclumab, Osimertinib and AZD4635. Results have been posted on the registry.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03381274
- Phase: 1/2
- Setting: A Multiarm, Open-label, Multicenter, Phase 1b/2 Study to Evaluate Novel Combination Therapies in Subjects With Previously Treated Advanced EGFRm NSCLC
- Sponsor: MedImmune LLC
- Enrolled: 43
- Outcomes: Percentage of Participants With Objective Response (OR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 in Part 2: Oleclumab Dose 2 + Osimertinib Dose 1 19%; Overall Survival (OS) for Parts 1 and 2: Oleclumab Dose 1 + Osimertinib Dose 1 21.9 months vs Oleclumab Dose 2 + Osimertinib Dose 1 24.8 months vs Oleclumab Dose 1 + AZD4635 Dose 1 16.4 months vs Oleclumab Dose 1 + AZD4635 Dose 2 27.4 months vs Oleclumab Dose 2 + AZD4635 Dose 2 7.1 months; Progression Free Survival (PFS) for Parts 1 and 2: Oleclumab Dose 1 + Osimertinib Dose 1 6.5 months vs Oleclumab Dose 2 + Osimertinib Dose 1 11 months vs Oleclumab Dose 1 + AZD4635 Dose 1 1.4 months vs Oleclumab Dose 1 + AZD4635 Dose 2 1.8 months vs Oleclumab Dose 2 + AZD4635 Dose 2 1.9 months

## Sources

- ClinicalTrials.gov NCT03381274: https://clinicaltrials.gov/study/NCT03381274

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Oleclumab](https://onco.cc/drugs/oleclumab/), [Osimertinib](https://onco.cc/drugs/osimertinib/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)
- key papers: [CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief Report](https://onco.cc/key-papers/paper-nct03381274-j-thorac-oncol-2023/)

---
JSON: https://onco.cc/api/v1/entities/nct03381274.json